196 related articles for article (PubMed ID: 15553660)
1. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study.
Moretti M; Bottrighi P; Dallari R; Da Porto R; Dolcetti A; Grandi P; Garuti G; Guffanti E; Roversi P; De Gugliemo M; Potena A;
Drugs Exp Clin Res; 2004; 30(4):143-52. PubMed ID: 15553660
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study).
Marchioni CF; Polu JM; Taytard A; Hanard T; Noseda G; Mancini C
Int J Clin Pharmacol Ther; 1995 Nov; 33(11):612-8. PubMed ID: 8688986
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study.
Crisafulli E; Coletti O; Costi S; Zanasi E; Lorenzi C; Lucic S; Fabbri LM; Bertini M; Clini EM
Clin Ther; 2007 Sep; 29(9):2001-9. PubMed ID: 18035199
[TBL] [Abstract][Full Text] [Related]
4. Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation.
Calverley PM; Page C; Dal Negro RW; Fontana G; Cazzola M; Cicero AF; Pozzi E; Wedzicha JA
Int J Chron Obstruct Pulmon Dis; 2019; 14():2733-2744. PubMed ID: 31819405
[TBL] [Abstract][Full Text] [Related]
5. Erdosteine for COPD exacerbations.
Drug Ther Bull; 2008 Oct; 46(10):79-80. PubMed ID: 18832259
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data.
Cazzola M; Floriani I; Page CP
Pulm Pharmacol Ther; 2010 Apr; 23(2):135-44. PubMed ID: 19854285
[TBL] [Abstract][Full Text] [Related]
7. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study.
Dal Negro RW; Wedzicha JA; Iversen M; Fontana G; Page C; Cicero AF; Pozzi E; Calverley PMA; ;
Eur Respir J; 2017 Oct; 50(4):. PubMed ID: 29025888
[TBL] [Abstract][Full Text] [Related]
8. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year.
Zhou Y; Wang X; Zeng X; Qiu R; Xie J; Liu S; Zheng J; Zhong N; Ran P
Respirology; 2006 Sep; 11(5):603-10. PubMed ID: 16916334
[TBL] [Abstract][Full Text] [Related]
9. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.
Calverley PM; Sanchez-Toril F; McIvor A; Teichmann P; Bredenbroeker D; Fabbri LM
Am J Respir Crit Care Med; 2007 Jul; 176(2):154-61. PubMed ID: 17463412
[TBL] [Abstract][Full Text] [Related]
10. [Theophylline in the treatment of chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled study].
Zhou YM; Wang XP; Zeng XY; Qiu R; Xie JF; Liu SM; Zheng JP; Zhong NS; Ran PX
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Sep; 29(9):577-82. PubMed ID: 17129461
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial.
Dal Negro RW; Visconti M; Turco P
Pulm Pharmacol Ther; 2015 Aug; 33():47-51. PubMed ID: 26116425
[TBL] [Abstract][Full Text] [Related]
12. [Multicenter, controlled, double-blind study of the efficacy and tolerance of Vectrine (erdostein) versus placebo in the treatment of stabilized chronic bronchitis with hypersecretion].
Aubier M; Berdah L
Rev Mal Respir; 1999 Sep; 16(4):521-8. PubMed ID: 10549062
[TBL] [Abstract][Full Text] [Related]
13. Erdosteine enhances airway response to salbutamol in patients with mild-to-moderate COPD.
Dal Negro R; Visconti M; Trevisan F; Bertacco S; Micheletto C; Tognella S
Ther Adv Respir Dis; 2008 Oct; 2(5):271-7. PubMed ID: 19124377
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease.
Moretti M
Expert Rev Respir Med; 2007 Dec; 1(3):307-16. PubMed ID: 20477170
[TBL] [Abstract][Full Text] [Related]
15. Erdosteine: its relevance in COPD treatment.
Moretti M
Expert Opin Drug Metab Toxicol; 2009 Mar; 5(3):333-43. PubMed ID: 19331595
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
Rogliani P; Matera MG; Page C; Puxeddu E; Cazzola M; Calzetta L
Respir Res; 2019 May; 20(1):104. PubMed ID: 31133026
[TBL] [Abstract][Full Text] [Related]
17. Tiotropium in COPD patients not previously receiving maintenance respiratory medications.
Adams SG; Anzueto A; Briggs DD; Menjoge SS; Kesten S
Respir Med; 2006 Sep; 100(9):1495-503. PubMed ID: 16698259
[TBL] [Abstract][Full Text] [Related]
18. A controlled multicenter pediatric study in the treatment of acute respiratory tract diseases with the aid of a new specific compound, erdosteine (IPSE, Italian Pediatric Study Erdosteine).
Titti G; Lizzio A; Termini C; Negri P; Fazzio S; Mancini C
Int J Clin Pharmacol Ther; 2000 Aug; 38(8):402-7. PubMed ID: 10984014
[TBL] [Abstract][Full Text] [Related]
19. The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding.
Tashkin DP
Am J Med; 2006 Oct; 119(10 Suppl 1):63-72. PubMed ID: 16996901
[TBL] [Abstract][Full Text] [Related]
20. Investigating new standards for prophylaxis in reduction of exacerbations--the INSPIRE study methodology.
Seemungal T; Stockley R; Calverley P; Hagan G; Wedzicha JA
COPD; 2007 Sep; 4(3):177-83. PubMed ID: 17729060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
